KalVista: Sebetralstat Nears Approval, Aiming For 2025 Launch (NASDAQ:KALV)KalVista: Sebetralstat Nears Approval, Aiming For 2025 Launch (NASDAQ:KALV)
koto_feja KalVista Pharmaceuticals (NASDAQ:KALV) is a clinical-stage pharmaceutical company that develops oral small-molecule therapies for hereditary angioedema [HAE]. KALV’s inhibitors[...]